The FDA expanded the indication of eculizumab (Soliris) to include pediatric patients ages 6 and older with generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback